Dexamethasone 4mg/mL injection changes
21st October 2014
Dexamethasone injection 4mg/mL (Organon) has been acquired by Aspen pharmaceuticals. They have reformulated the product and it now contains 3.8mg/mL dexamethasone, available as a 1mL vial, which requires storage in a fridge.
The other dexamethasone injectable formulations in the UK are 3.3mg/mL (Hamelyn and Hospira), available as 1mL glass ampoules and do not require refrigeration.
These changes have significant implications for prescribing, administration and storage, with potential further risks for confusion and error above those already ready present due to the different dexamethasone salts.
MHRA has highlighted the issues in the October 2014 Drug Safety Update and UKMI has produced a safety assessment report summarizing the changes, the differences between the products and the potential next steps.
- Dexamethasone 4mg/mL injection changes
- Denosumab updated SPC and information on ONJ and hypocalcaemia
- Buscopan and baclofen confusion
- Diclofenac dose reduced in Canada
- Electronic prescribing for controlled drugs - DH consultation
- Demeclocycline 150mg capsules supply issue
- Supplementary information on wholesale dealer and controlled drugs licences in England
- Domperidone restricted to a POM
- Liverpool Care pathway replaced by five Priorities for Care
- CQC annual report: safer management of controlled drugs